Episode Details

Join Dr. Jeffrey Gladden, Steve Reiter and Dr. Paul Harch in this episode of the Gladden Longevity podcast. Paul G. Harch, M.D. is a clinical private practice and academic physician who made a discovery in 1989 treating divers with chronic brain decompression illness. He found that the wounds in these divers' brains were similar to chronic extremity wounds, but they were only responsive to a non-traditional dose of hyperbaric oxygen therapy. In 2004, based on the life-extending outcomes of treating patients with dementia, he proposed the longevity potential of HBOT to the American Academy of Anti-Aging Medicine. In March 2020, he proved the efficacy of HBOT in mild TBI persistent post-concussion syndrome in a randomized controlled trial and proposed HBOT application to COVID. Now in its 3rd edition, HBOT is explained as an epigenetic therapy with expected revolutionary effects on medicine, neurology, and longevity. In this episode, they talk about HBOT as a dual-component drug, the primary target of HBOT, and how HBOT is a treatment for wounds and inflammatory conditions in any location and of any duration. Do you know the medical benefits of HBOT? Listen to find out more.

Listen to this episode to learn about making a 100 the new 30, and living beyond 120!

Dr. Gladden considers Dr. Harch to be one of the fathers or grandfathers of hyperbaric oxygen therapy (00:58).

Dr. Harch explains what drew him into researching hyperbaric oxygen therapy. (1:35)

Dr. Harch discusses why hyperbaric oxygen therapy is used for scuba divers or diving medicine. (3:05)

Dr. Harch mentions how important the first hour is when using hyperbaric oxygen to treat injuries divers may have. (6:05)

Dr. Gladden shares that molecular hydrogen is a way to modulate reperfusion injury. (7:00)

Dr. Harch notes that if you can give the hyperbaric treatment in the first hour, it totally inhibits those attachment molecules on the white blood cells from expressing themselves. (9:45)